Sunday, 22 July 2018

  • it
  • en

Research & Development

ERA-Net EuroNanoMed Project

7th Framework Programme Theme


is a strategic priority for Europe because technologies related to this sector have a vast potential for developing public welfare and economic growth, changing the way of life of citizens in many fields of application: healthcare, information and communication technologies (ICT), environment.

Nanomedicine is the application of nanotechnology to achieve breakthroughs in healthcare. It exploits the improved and often novel physical, chemical and biological properties of materials at the nanometer scale. Nanomedicine has the potential to enable early detection and prevention, and to essentially improve diagnosis, treatment and follow-up of diseases.

Nanomedicine is defined as the science and technology of diagnosing, treating and preventing disease and traumatic injury, of relieving pain, and of preserving and improving human health, using molecular tools and molecular knowledge of the human body. It was perceived as embracing five main sub-disciplines that in many ways are overlapping and underpinned by the following common technical issues: analytical tools, nanoimaging, nanomaterials and nanodevices, novel therapeutics and drug delivery systems, clinical, regulatory and toxicological issues.


The ERA-Net for research programmes on Nanomedicine (EuroNanoMed) is funded under the ERA-Net scheme of the European Commission for the period of 2009-2012; it is supported by the European Commission in the 7th Framework Programme (FP7). This initiative is born from the will of 24 European member states and regions to work together in order to support trans-national collaborative RTD projects between academic laboratories, companies, especially SME’s, and clinicians/public health setting, in the field of Nanomedicine, by coordinating their respective national or regional publicly funded programmes. The main objective of EuroNanoMed is to foster the competitiveness of European Nanomedicine actors, supporting both: 1)the transfer between partners from industry, academia and clinical/public health setting; 2)the research of industrial companies in their multidisciplinary trans-national strategic partnership with academics and clinical/public health setting, to achieve innovative products and technologies for the patients that could reach the market in the short/medium term. In consequence, EuroNanoMed will develop coordinated European-wide programmes based on 2 common joint trans-national calls and funding. The thematic of these two calls will focus on regenerative medicine, diagnostics and targeted delivery systems.


Over the last years, Europe has been successful in a lot of efforts made in basic research dedicated to nanotechnologies. However, within the Nanomedicine field in Europe, a critical issue concerns especially the RTD players: their capability to move effectively innovation from basic knowledge into either industrial applications or clinical applications, i.e. translational research. To not be excluded from this sector, it is time for Europe and European states to support efforts to bridge the gap between research and its clinical/public health and commercial application, especially SMEs, to reach a sufficient level of competitiveness and a critical size in terms of their R&D projects portfolio, their scientific and clinical excellence.

For that purpose, EuroNanoMed is a major opportunity for scientists from European industry (especially start-ups and SMEs, whose participation is encouraged), academic and clinical/public health communities to take benefit from the flexible co-ordination of several existing national/regional funding programmes to enlarge their possibilities for partnerships, to fruitful cross-border partnerships. A similar multidisciplinary translational approach in the field with an international focus as the one developed in EuroNanoMed does not yet exist. This initiative will bring together the academic, the clinical/public health and the industrial research teams to develop innovative diagnostic and therapeutic solutions for the patient, thus enhancing the competitiveness of the European health industry.

Co-funded Project by:

Unione Europea

Repubblica Italiana

Regione Veneto

©2010-2016 Veneto Nanotech ScpA in liq.
SEDE LEGALE: Piazza Salvemini, 13 I-35131 Padova - Italy
SEDE AMMINISTRATIVA: c/o CNR, Corso Stati Uniti, 4 I-35127 Padova - Italy
Tel. +39 331 7413295
C.F., iscrizione Reg. Imprese e P.IVA 03845260284